Beschreibung:
<jats:p>Genomic markers are among the strongest prognostic factors in chronic lymphocytic leukemia (CLL). Chromosomal aberrations, <i>IGHV</i> and <i>TP53</i> mutation status are well-established and essential to discriminate between a more indolent course of disease and a high-risk CLL, which requires an alternative treatment regimen. In addition, a variety of gene mutations with unclear prognostic value have been identified: <i>SF3B1</i>, <i>ATM</i>, and <i>BIRC3</i> may describe CLL with adverse outcome, whereas <i>NOTCH1</i> is predictive for resistance against CD20 antibodies. Integration of novel drivers into a small set of key pathways forms the basis for future pathogenetic and therapeutic implications.</jats:p>